Novel agents and associated toxicities of inhibitors of the PI3k/Akt/mtor pathway for the treatment of breast cancer

Current Oncology

Volumn 22, Issue 1, 2015, Pages 33-48

  Chia, Stephen ^a   Gandhi, S ^b   Joy, A A ^c   Edwards, S ^d   Gorr, M ^e   Hopkins, S ^e   Kondejewski, J ^f   Ayoub, J P ^g   Califaretti, N ^h   Rayson, D ⁱ   Dent, S F ^j  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d Eastern Health Canada   (Canada)

^e Royal Victoria Hospital Barrie   (Canada)

^f SNELL Medical Communication   (Canada)

^g UNIVERSITÉ DE MONTRÉAL   (Canada)

^h Grand River Regional Cancer Centre   (Canada)

ⁱ DALHOUSIE UNIVERSITY   (Canada)

^j OTTAWA REGIONAL CANCER CENTRE   (Canada)

more..

Author keywords

Adverse events; Breast cancer; Everolimus; PI3k Akt mtor

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO [3', 2':4, 5] FURO [3, 2 D] PYRIMIDINE; 3 (2 AMINO 5 BENZOXAZOLYL) 1 ISOPROPYL 1H PYRAZOLO [3, 4 D] PYRIMIDIN 4 AMINE; 4 AMINO N [1 (4 CHLOROPHENYL) 3 HYDROXYPROPYL] 1 (7H PYRROLO [2, 3 D] PYRIMIDIN 4 YL) 4 PIPERIDINECARBOXAMIDE; 8 [4 (1 AMINOCYCLOBUTYL) PHENYL] 9 PHENYL 1, 2, 4 TRIAZOLO [3, 4 F] [1, 6] NAPHTHYRIDIN 3 (2H) ONE; ALPELISIB; ANTIBIOTIC AGENT; APITOLISIB; BUPARLISIB; CORTICOSTEROID; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; EXEMESTANE; GEDATOLISIB; IPATASERTIB; MAMMALIAN TARGET OF RAPAMYCIN; MOUTHWASH; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PICTILISIB; PILARALISIB; PLACEBO; PROTEIN KINASE B; RAPAMYCIN; RIDAFOROLIMUS; TAMOXIFEN; TASELISIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; UPROSERTIB; VOXTALISIB;

ARTICLE; BREAST CANCER; CANADA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; HYPERGLYCEMIA; IATROGENIC DISEASE; IMMUNE DEFICIENCY; INTERVENTION STUDY; MEDICAL LITERATURE; META ANALYSIS (TOPIC); MOUTH HYGIENE; NONINFECTIOUS PNEUMONITIS; NURSE; ONCOLOGIST; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT EDUCATION; PATIENT MONITORING; PHARMACIST; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; PROPHYLAXIS; PROTEIN EXPRESSION; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SIGNAL TRANSDUCTION; STOMATITIS;

EID: 84922945711     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.22.2393     Document Type: Article

References (38)

1. Saini KS, Loi S, de Azambuja A, et al. Targeting the pi3k/Akt/ mtor and Raf/mek/erk pathways in the treatment of breast cancer. Cancer Treat Rev 2013:39;935–46.
2. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumors. Nature2012;490:61–70.
3. Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature2013;502:333–9.
4. Curtis C, Shah SP, Chn SF, et al. The genomic and transcrip-tomic architecture of 2,000 breast tumours reveals novel subgroups. Nature2012;486:346–52.
5. Courtney KD, Corcoran RB, Engelman JA. The pi3k pathway as drug target in human cancer. J Clin Oncol2010;28:1075–83.
6. Grabiner BC, Nardi V, Birsoy K, et al. A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov2014;4:554–63.
7. Castaneda CA, Cortes–Funes H, Gomez HL, Ciruelos EM. The phosphatidyl inositol 3-kinase/Akt signaling pathway in breast cancer. Cancer Metastasis Rev 2010;29:751–9.
8. Miller TW, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res2011;13:224.
9. Rugo HS, Keck S. Reversing hormone resistance: have we found the golden key? J Clin Oncol2012;30:2707–9.
10. Rugo HS, Pritchard KI, Gnant M. Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from bolero-2. Ann Oncol2014;25:808–15.
11. Burris HA 3rd. Overcoming acquired resistance to anticancer therapy: focus on the pi3k/Akt/mtor pathway. Cancer Chemother Pharmacol 2013;71:829–42.
12. Akinleye A, Avvaru P, Furqan M, Song Y, Liu D. Phosphati-dylinositol 3-kinase (pi3k) inhibitors as cancer therapeutics. J Hematol Oncol2013;6:88.
13. Wander SA, Hennessy BT, Slingerland JM. Next-generation mtor inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest2011;121:1231–41.
14. Demetri GD, Chawla SP, Ray–Coquard I, et al. Results of an international randomized phase iii trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol 2013;31:2485–92.
15. Saura C, Bendell J, Jerusalem G, et al. Phase ib study of buparlisib plus trastuzumab in patients with her2-posi-tive advanced or metastatic breast cancer that has progressed on trastuzumab-based therapy. Clin Cancer Res2014;20:1935–45.
16. Gonzalez–Angulo AM, Juric D, Argiles G, et al. Safety, phar-macokinetics, and preliminary activity of the alpha-specific pi3k inhibitor BYL719: results from the first-in-human study [abstract 2531]. J Clin Oncol 2013;31:. [Available online at: http://meetinglibrary.asco.org/content/114843-132; cited January 14, 2015]
17. Ramanathan RK, McDonough SL, Kennecke HF, et al. A phase ii study of MK-2206, an allosteric inhibitor of Akt as second-line therapy for advanced gastric and gastroesophageal junction (gej) cancer: a swog Cooperative Group trial (S1005) [abstract 4041]. J Clin Oncol 2014;32:. [Available online at: http://meetinglibrary.asco.org/content/126933-144; cited January 14, 2015]
18. Konstantinopoulos P, Makker V, Barry WT, et al. Phase ii, single stage, cohort expansion study of MK-2206 in recurrent endometrial serous cancer [abstract 5515]. J Clin Oncol 2014;32:. [Available online at: http://meetinglibrary.asco.org/content/134284-144; cited January 14, 2015]
19. Mayer IA, Abramson VG, Isakoff SJ, et al. Stand Up to Cancer phase ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2–negative metastatic breast cancer. Clin Oncol2014;32:1202–9.
20. Besse B, Soria J, Gomez–Roca C, et al. A phase ib study to evaluate the pi3-kinase inhibitor GDC-0941 with paclitaxel (p) and carboplatin (c), with and without bevacizumab (bev), in patients with advanced non-small cell lung cancer (nsclc) [abstract 3044]. J Clin Oncol 2011;29:. [Available online at: http://meetinglibrary.asco.org/content/81203-102; cited January 14, 2015]
21. Ahnert JR, Schuler MH, Machiels JPH, et al. Phase ib study of BEZ235 plus either paclitaxel (ptx) in advanced solid tumors (ast) or ptx plus trastuzumab (tz) in her2+ breast cancer (bc) [abstract 627]. J Clin Oncol 2014;32:. [Available online at: http://meetinglibrary.asco.org/content/131298-144; cited January 14, 2015]
22. Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with hr+ breast cancer: bolero-2 final progression-free survival analysis. Adv Therapy 2013;30:870–84. [Erratum in: Adv Ther 2014;31:1008–9]
23. Piccart M, Hortobagyi GN, Campone M, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: overall survival results from bolero-2. Ann Oncol2014; 25:2357–62.
24. Bachelot T, Bourgier C, Cropet C, et al. Randomized phase ii trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2–negative metastatic breast cancer with prior exposure to ais: a gineco study. J Clin Oncol2012;30:2718–24.
25. Peterson ME. Management of adverse events in patients with hormone receptor-positive breast cancer treated with everoli-mus: observations from a phase iii clinical trial. Support Care Cancer2013;21:2341–9.
26. Rugo HS, Pritchard KI, Gnant M. Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from bolero-2. Ann Oncol2014;25:808–15.
27. Aapro M, Andre F, Blackwell K, et al. Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. Ann Oncol2014;25:763–73.
28. A lbiges L, Chamming’s F, Duclos B, et al. Incidence and manage-ment of mtor inhibitor–associated pneumonitis in patients with metastatic renal cell carcinoma. Ann Oncol 2012;23:1943–53.
29. Divers J. Management of stomatitis associated with mtor inhibitors in hormone receptor–positive/her-2 negative advanced breast cancer: clinical experience from a single center. Oncol Nurs Forum 2013;40:E223–4.
30. Rugo HS, Yao JC, Hortobagyi GN, et al. Meta-analysis of stomatitis incidence in everolimus (eve) clinical studies and its relationship with effcacy [abstract 645]. J Clin Oncol 2014;32:. [Available online at: http://meetinglibrary.asco.org/ content/133921-144; cited January 14, 2015]
31. Lueftner D, Schuetz F, Grischke EM, et al. Breast cancer treatment with everolimus and exemestane for er+ women: results of the first interim analysis of the noninterventional trial brawo [abstract 578]. J Clin Oncol 2014;32:. [Available online at: http://meetinglibrary.asco.org/content/133132-144; cited January 14, 2015]
32. Fasching PA, Decker T, Schneeweiss A, et al. Breast cancer treatment with everolimus and exemestane for er+ women— results of the 2nd interim analysis of the non-interventional trial brawo [abstract LBA9]. Ann Oncol 2014;25(suppl 4):. [Available online at: http://annonc.oxfordjournals.org/content/25/suppl_4/mdu438.6.abstract?sid=1c3bb455-11c3-42f 3-91b4-8890a3e33927; cited January 19, 2015]
33. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Goldenberg R, Punthakee Z. Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome. Can J Diabetes 2013;37(suppl 1):S8–11.
34. Miller D, Berard L, Cheng A, et al. on behalf of the Canadian Diabetes Association. Self-monitoring of blood glucose in people with type 2 diabetes: Canadian Diabetes Association briefing document for healthcare providers. Can J Diabetes 2011;35:317–19.
35. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Harper W, Clement M, Goldenberg R, et al. Pharmacologic management of type 2 diabetes. Can J Diabetes 2013;37(suppl 1):S61–8.
36. Edwards SJ, Abbott R, Edwards J, et al. Outcomes assessment of a pharmacist-directed seamless care program in an ambulatory oncology clinic. J Pharm Pract2014;27:46–52.
37. Canadian Association of Nurses in Oncology/Association canadienne des infirmières en oncologie (cano/acio). CANO/ ACIO Position Statement on Cancer Chemotherapy Administration and Care: Oral Chemotherapy Supplement. Vancouver, BC: cano/acio; 2013. [Available online at: http://www.cano-acio.ca/~ASSETS/DOCUMENT/CANO-Position-statement-Supplement-On-Oral-Chemotherapy-Final%20 July%202013-D2.pdf; cited November 4, 2014.]
38. Bandura A. Self-effcacy: toward a unifying theory of behavioral change. Psychol Rev 1977;84:191–215. [Available online at: http://www.uky.edu/~eushe2/Bandura/Bandura1977PR. pdf; cited January 19, 2015]